=> index bioscience medicine

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:17:56 ON 28 FEB 2008

72 FILES IN THE FILE LIST IN STNINDEX

=> S (SKRP or DUS19 or CG7042 or(dual (w) specificity (w) phosphatase))
18 FILE AGRICOLA
5 FILE AQUASCI
24 FILE BIOENG
433 FILE BIOSIS
45 FILE BIOTECHABS
45 FILE BIOTECHDS
161 FILE BIOTECHNO
16 FILE CABA
598 FILE CAPLUS
1 FILE CIN
7 FILE CONFSCI
48 FILE DDFU
1922 FILE DGENE
25 FILE DISSABS
58 FILE DRUGU
5 FILE EMBAL
342 FILE EMBASE
317 FILE ESBIOBASE
1315 FILE GENBANK
64 FILE IFIPAT
1 FILE IMSDRUGNEWS
1 FILE IMSRESEARCH
162 FILE LIFESCI
916 FILE MEDLINE
4 FILE NTIS
101 FILE PASCAL
8 FILE PHAR
52 FILES SEARCHED...
5 FILE PROMT
2 FILE PROUSDDR
596 FILE SCISEARCH
2 FILE SYNTHLINE
403 FILE TOXCENTER
479 FILE USGENE
564 FILE USPATFULL
1 FILE USPATOLD
66 FILE USPAT2
48 FILE WPIDS
48 FILE WPINDEX
2 FILE IPA
3 FILE NLDB

40 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STNINDEX

L1 QUE (SKRP OR DUS19 OR CG7042 OR(DUAL (W) SPECIFICITY (W) PHOSPHATASE))

=> d rank
F1 1922 DGENE
F2 1315 GENBANK
F3 916 MEDLINE
F4 598 CAPLUS
F5 596 SCISEARCH
F6 564 USPATFULL
F7 479 USGENE
F8 433 BIOSIS
F9 403 TOXCENTER
F10 342 EMBASE
F11 317 ESBIOBASE

```
F12      162  LIFESCI
F13      161  BIOTECHNO
F14      101  PASCAL
F15       66  USPAT2
F16       64  IFIPAT
F17       58  DRUGU
F18       48  DDFU
F19       48  WPIDS
F20       48  WPINDEX
F21       45  BIOTECHABS
F22       45  BIOTECHDS
F23       25  DISSABS
F24       24  BIOENG
F25       18  AGRICOLA

=> file f3-f6, f8-f14, f19

FILE 'MEDLINE' ENTERED AT 17:19:32 ON 28 FEB 2008

FILE 'CAPLUS' ENTERED AT 17:19:32 ON 28 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 17:19:32 ON 28 FEB 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 17:19:32 ON 28 FEB 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:19:32 ON 28 FEB 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 17:19:32 ON 28 FEB 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:19:32 ON 28 FEB 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:19:32 ON 28 FEB 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 17:19:32 ON 28 FEB 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 17:19:32 ON 28 FEB 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'PASCAL' ENTERED AT 17:19:32 ON 28 FEB 2008
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:19:32 ON 28 FEB 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

=> S L1
L2        4641 L1

=> S (gene or sequence or polynucleotide or clone or recombinant)
   6 FILES SEARCHED...
  11 FILES SEARCHED...
L3    12878385 (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)

=> S (gene or sequence or polynucleotide or clone or recombinant) (s) L2
  10 FILES SEARCHED...
L4        1511 (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)
               (S) L2
```

=> S (modulator or Effector or inhibitor) (s) L4
L5 321 (MODULATOR OR EFFECTOR OR INHIBITOR) (S) L4

=> S (composition or kit)(s) L5
L6 24 (COMPOSITION OR KIT)(S) L5

=> dup rem L6
PROCESSING COMPLETED FOR L6
L7 24 DUP REM L6 (0 DUPLICATES REMOVED)

=> d ibib abs L7 1-24

L7 ANSWER 1 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2008:59942 USPATFULL <<LOGINID::20080228>>
TITLE: Global Gene Expression Analysis of Human Bronchial Epithelial Cells Exposed to Cigarette Smoke, Smoke Condensates, or Components Thereof
INVENTOR(S): Jorgensen, Ellen D, South Salem, NY, UNITED STATES
Albino, Anthony P., New York, NY, UNITED STATES
Jin, Wendy, Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2008052789	A1	20080228
APPLICATION INFO.:	US 2005-593596	A1	20050329 (10)
	WO 2005-US10733		20050329
			20070727 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-557929P	20040330 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 7127
AB Aspects of the present invention concern the identification of several methods to analyze the genes that are modulated in normal human bronchial epithelial (NHBE) cells after exposure to cigarette smoke condensates (CSC) or cigarette smoke (CS). Embodiments described herein include methods to identify a gene that is modulated in response to exposure to CSC or CS, methods to identify tobacco products that have a reduced potential to contribute to tobacco-related disease, methods to make tobacco products that have a reduced potential to contribute to a tobacco-related disease, methods to identify a subject's predilection to acquire a tobacco related disease, the use of particular genes as biomarkers for tobacco-related disease, and patterns of gene expression or genetic signatures that are unique to each particular tobacco product.

L7 ANSWER 2 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2008:23867 USPATFULL <<LOGINID::20080228>>
TITLE: Methods of treatment and prevention using haloaryl substituted aminopurines
INVENTOR(S): Bennett, Brydon L., San Diego, CA, UNITED STATES
Ferguson, Gregory, San Diego, CA, UNITED STATES
Satoh, Yoshitaka, Poway, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2008021048	A1	20080124
APPLICATION INFO.:	US 2007-708150	A1	20070215 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2006-411413, filed on 26 Apr 2006, PENDING Continuation-in-part of Ser. No. US 2006-332617, filed on 12 Jan 2006, PENDING		

NUMBER DATE

PRIORITY INFORMATION: US 2005-643796P 20050113 (60)
US 2005-709980P 20050819 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 4488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are Aminopurine Compounds having the following structure: ##STR1##

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2008:11128 USPATFULL <<LOGINID::20080228>>
TITLE: Markers of pre-term labor
INVENTOR(S): Pennell, Craig, Toronto, CANADA
Lye, Stephen, Toronto, CANADA

NUMBER KIND DATE

PATENT INFORMATION: US 2008009552 A1 20080110
APPLICATION INFO.: US 2007-727179 A1 20070323 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2006-785147P 20060323 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCCARTHY TETRAULT LLP, BOX 48, SUITE 4700,, 66WELLINGTON STREET WEST, TORONTO, ON, M5K 1E6, CA
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 4078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel markers of pre-term labor, methods for assessing the status of pre-term labor using the markers, and methods for the diagnosis and therapy of pre-term labor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2007:212487 USPATFULL <<LOGINID::20080228>>
TITLE: Mutant BDNF gene introducing knockin mouse
INVENTOR(S): Kojima, Masami, Ikeda-shi, JAPAN
Hara, Tomoko, Ikeda-shi, JAPAN
Koshimizu, Hisatsugu, Ikeda-shi, JAPAN
Kashihara, Megumi, Ikeda-shi, JAPAN
Taguchi, Takahisa, Ikeda-shi, JAPAN
PATENT ASSIGNEE(S): NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, Tokyo-to, JAPAN (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2007186301 A1 20070809
APPLICATION INFO.: US 2007-649360 A1 20070104 (11)

NUMBER DATE

PRIORITY INFORMATION: JP 2006-397 20060105
JP 2006-116863 20060420
JP 2006-156879 20060606
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP, 1250 CONNECTICUT AVENUE, NW, SUITE 700, WASHINGTON, DC, 20036, US
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a non-human knockin animal having a mutation in a proBDNF gene wherein conversion from proBDNF to BDNF has been inhibited by the mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2007:177072 USPATFULL <<LOGINID::20080228>>
TITLE: Methods and reagents for the detection of melanoma
INVENTOR(S): Wang, Yixin, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): VERIDEX, LLC, Warren, NJ, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2007154889 A1 20070705
APPLICATION INFO.: US 2005-567025 A1 20050624 (10)
WO 2005-US22846 20050624
20060816 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2004-582906P 20040625 (60)
US 2004-612951P 20040924 (60)
US 2005-649725P 20050203 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
NUMBER OF CLAIMS: 221
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 4768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An assay for identifying a malignant melanocyte is conducted by determining whether differential expression of particular genes is indicative of melanoma exceed a cut-off value. The assay can be performed intra-operatively on lymph node tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2007:120920 USPATFULL <<LOGINID::20080228>>
TITLE: Primers for synthesizing full-length cDNA and their use
INVENTOR(S): Ota, Toshio, Fujisawa-shi, JAPAN
Isogai, Takao, Inashiki-gun, JAPAN
Nishikawa, Tetsuo, Tokyo, JAPAN
Hayashi, Koji, Ichihara-shi, JAPAN
Saito, Kaoru, Kisarazu-shi, JAPAN
Yamamoto, Junichi, Kisarazu-shi, JAPAN
Ishii, Shizuko, Kisarazu-shi, JAPAN
Sugiyama, Tomoyasu, Kisarazu-shi, JAPAN
Wakamatsu, Ai, Kisarazu-shi, JAPAN
Nagai, Keiichi, Tokyo, JAPAN

Otsuki, Tetsuji, Kisarazu-shi, JAPAN
PATENT ASSIGNEE(S): RESEARCH ASSOCIATION FOR BIOTECHNOLOGY (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007105122	A1	20070510
APPLICATION INFO.:	US 2004-917503	A1	20040813 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-629469, filed on 28 Jul 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-248036	19990929
	JP 1999-300253	19990827
	JP 2000-118776	20000111
	JP 2000-183767	20000502
	JP 2000-241899	20000609
	US 1999-159590P	19991018 (60)
	US 2000-183322P	20000217 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 96883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Primers for synthesizing full-length cDNAs and their use are provided. 5602 cDNA encoding a human protein has been isolated and nucleotide sequences of 5'-, and 3'-ends of the cDNA have been determined. Furthermore, primers for synthesizing the full-length cDNA have been provided to clarify the function of the protein encoded by the cDNA. The full-length cDNA of the present invention containing the translation start site provides information useful for analyzing the functions of the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2007:88980 USPATFULL <<LOGINID::20080228>>
TITLE: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VACCINIA REGULATORY GENES AND USES THEREOF
INVENTOR(S): Bentwich, Itzhak, 65 Kfar Daniel, Kfar Daniel, ISRAEL 73125
PATENT ASSIGNEE(S): ROSETTA GENOMICS, Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007077553	A1	20070405
APPLICATION INFO.:	US 2003-605840	A1	20031030 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSETTA GENOMICS, 10 PLAUT-STREET SCIENCE PARK, P.O. BOX 2061, REHOVOT, 76706, IL
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 126036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a group of novel viral RNA regulatory genes, here identified as "viral genomic address messenger genes" or "VGAM genes", and as "Viral genomic record" or "VGR genes". VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an "operon"-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively

encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2007:69343 USPATFULL <<LOGINID::20080228>>
TITLE: Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
INVENTOR(S): Albers, Ronald J., San Diego, CA, UNITED STATES
Ayala, Leticia, San Diego, CA, UNITED STATES
Chureen, Steven S., San Diego, CA, UNITED STATES
Delgado Mederos, Maria Mercedes, San Diego, CA, UNITED STATES
Hilgraf, Robert, San Diego, CA, UNITED STATES
Hegde, Sayee G., San Diego, CA, UNITED STATES
Hughes, Kevin, San Antonio, TX, UNITED STATES
Kois, Adam, San Diego, CA, UNITED STATES
Plantevin-Krenitsky, Veronique, San Diego, CA, UNITED STATES
McCarrick, Meg, San Diego, CA, UNITED STATES
Nadolny, Lisa, San Diego, CA, UNITED STATES
Palanki, Moorthy S.S., Encinitas, CA, UNITED STATES
Sahasrabudhe, Kiran, San Diego, CA, UNITED STATES
Sapienza, John, Chula Vista, CA, UNITED STATES
Satoh, Yoshitaka, Poway, CA, UNITED STATES
Sloss, Marianne K., San Diego, CA, UNITED STATES
Sudbeck, Elise, San Diego, CA, UNITED STATES
Wright, Jonathan, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007060598	A1	20070315
APPLICATION INFO.:	US 2006-411413	A1	20060426 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2006-332617, filed on 12 Jan 2006, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-643796P	20050113 (60)
	US 2005-709980P	20050819 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
LINE COUNT: 4559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are Aminopurine Compounds having the following structure: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2007:36283 USPATFULL <<LOGINID::20080228>>
TITLE: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VACCINIA REGULATORY GENES AND USES THEREOF
INVENTOR(S): Bentwich, Itzhak, 65 Kfar Daniel, Kfar Daniel, ISRAEL 73125
PATENT ASSIGNEE(S): ROSETTA GENOMICS, Rehovot, ISRAEL (non-U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007031823	A1	20070208
APPLICATION INFO.:	US 2003-604943	A1	20030828 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-441241P	20030117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSETTA-GENOMICS, 10 PLAUT-STREET SCIENCE PARK, P.O. BOX 2061, REHOVOT, 76706, IL
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 61464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a group of novel viral RNA regulatory genes, here identified as "viral genomic address messenger genes" or "VGAM genes", and as "genomic record" or "GR" genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2006:334729 USPATFULL <<LOGINID::20080228>>
TITLE: Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
INVENTOR(S): Albers, Ronald J., San Diego, CA, UNITED STATES
Ayala, Leticia, San Carlos, CA, UNITED STATES
Clareen, Steven S., San Diego, CA, UNITED STATES
Delgado Mederos, Maria Mercedes, San Diego, CA, UNITED STATES
Hilgraf, Robert, San Diego, CA, UNITED STATES
Hegde, Sayee G., San Diego, CA, UNITED STATES
Hughes, Kevin, San Antonio, TX, UNITED STATES
Kois, Adam, San Diego, CA, UNITED STATES
Plantevin-Krenitsky, Veronique, San Diego, CA, UNITED STATES
McCarrick, Meg, San Diego, CA, UNITED STATES
Nadolny, Lisa, San Diego, CA, UNITED STATES
Palanki, Moorthy S.S., Encinitas, CA, UNITED STATES
Sahasrabudhe, Kiran, San Mateo, CA, UNITED STATES
Sapienza, John, Chula Vista, CA, UNITED STATES
Satoh, Yoshitaka, Poway, CA, UNITED STATES
Sloss, Marianne K., San Diego, CA, UNITED STATES
Sudbeck, Elise, San Diego, CA, UNITED STATES
Wright, Jonathan, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006287344	A1	20061221
APPLICATION INFO.:	US 2006-332617	A1	20060112 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-643796P	20050113 (60)
	US 2005-709980P	20050819 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 4390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are Aminopurine Compounds having the following structure: ##STR1##

wherein R.sup.1, R.sup.2 and and R.sup.3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2006:327908 USPATFULL <<LOGINID::20080228>>
TITLE: Kinase peptides and antibodies
INVENTOR(S): Muraca, Patrick J., Pittsfield, MA, UNITED STATES
PATENT ASSIGNEE(S): Nuclea Biomarkers LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006281111	A1	20061214
APPLICATION INFO.:	US 2006-435570	A1	20060517 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2006-1102	20060119
	US 2005-682115P	20050518 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SONNENSCHEIN NATH & ROSENTHAL LLP, FOR PAULA EVANS, P.O. BOX 061080, WACKER DRIVE STATION, SEARS TOWER, CHICAGO, IL, 60606-1080, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel kinase peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of a kinase-mediated disease, as well as for determining or monitoring the efficacy of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2006:302346 USPATFULL <<LOGINID::20080228>>
TITLE: Solid forms of a JNK inhibitor
INVENTOR(S): Saindane, Manohar, Monmouth Junction, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006258706	A1	20061116
APPLICATION INFO.:	US 2006-414630	A1	20060427 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-676693P	20050429 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 55

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Page(s)
LINE COUNT: 2362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system (CNS) injury/damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2006:294891 USPATFULL <<LOGINID::20080228>>
TITLE: Lung cancer prognostics
INVENTOR(S): Raponi, Mitch, San Diego, CA, UNITED STATES
Yu, Jack X., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20062520 57	A1	20061109
APPLICATION INFO.:	US 2005-290215	A1	20051130 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-632053P	20041130 (60)
	US 2005-655573P	20050223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 7271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of providing a prognosis of lung cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2006:288464 USPATFULL <<LOGINID::20080228>>
TITLE: Method for identifying nucleic acid molecules associated with angiogenesis
INVENTOR(S): Gonda, Thomas John, Chapel Hill, AUSTRALIA
Kremmidiotis, Gabriel, Flagstaff Hill, AUSTRALIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20062464 52	A1	20061102
APPLICATION INFO.:	US 2004-550533	A1	20040326 (10)
	WO 2004-AU383		20040326
			20060428 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AU 2003-2003901511	20030328

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JENKINS, WILSON, TAYLOR & HUNT, P. A., 3100 TOWER BLVD,

SUITE 1200, DURHAM, NC, 27707, US
NUMBER OF CLAIMS: 136
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the identification of a nucleic acid molecule differentially expressed in an in vitro model of a biological system, comprising the steps of: (1) harvesting cells from the model system at predetermined time points; (2) obtaining total RNA from the cells harvested at each time point; (3) preparing cDNA from the total RNA from each time point to provide a plurality of pools of cDNA; (4) performing a suppression subtractive hybridization (SSH) on the cDNA pools from each time point sequentially so as to progressively amplify cDNAs derived from nucleic acid molecules differentially expressed from one time period to the next.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2005:189388 USPATFULL <<LOGINID::20080228>>
TITLE: Molecular scaffolds for kinase ligand development
INVENTOR(S): Artis, Dean R., Kensington, CA, UNITED STATES
Bremer, Ryan E., Oakland, CA, UNITED STATES
Gillette, Samuel J., Oakland, CA, UNITED STATES
Hurt, Clarence R., San Ramon, CA, UNITED STATES
Ibrahim, Prabha L., Mountain View, CA, UNITED STATES
Zuckerman, Rebecca L., Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Plexxikon, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005164300	A1	20050728
APPLICATION INFO.:	US 2004-941635	A1	20040915 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-503277P	20030915 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278, US
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 19944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Molecular scaffolds for compounds active on protein kinases are described, along with methods for using such scaffolds for kinase ligand development. The use of kinase structural information, exemplified with PIM-1 crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate particular kinases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2005:170863 USPATFULL <<LOGINID::20080228>>
TITLE: IL-18 binding proteins
INVENTOR(S): Ghayur, Tariq, Holliston, MA, UNITED STATES
Labkovsky, Boris, Wales, MA, UNITED STATES
Voss, Jeffrey W., Holden, MA, UNITED STATES
Green, Larry, San Francisco, CA, UNITED STATES
Babcook, John, Vancouver, CANADA
Jia, Xiao-chi, Los Angeles, CA, UNITED STATES
Wieler, James, Beverly, MA, UNITED STATES
Kang, Jaspal Singh, Surrey, CANADA
Hedberg, Brad, Vancouver, CANADA

	NUMBER	KIND	DATE

---------- ------ --------
PATENT INFORMATION: US 2005147610 A1 20050707
APPLICATION INFO.: US 2004-988360 A1 20041112 (10)

NUMBER DATE
---------- --------
PRIORITY INFORMATION: US 2003-519474P 20031112 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ABBOTT BIORESEARCH, 100 RESEARCH DRIVE, WORCESTER, MA, 01605-4314, US
NUMBER OF CLAIMS: 79
EXEMPLARY CLAIM: 1
LINE COUNT: 6364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2005:138806 USPATFULL <<LOGINID::20080228>>
TITLE: PROTEIN THAT MODULATES THE STABILITY OF TRANSCRIPTIONAL REGULATORY COMPLEXES REGULATING NUCLEAR HORMONE RECEPTOR ACTIVITY, DNA ENCODING SAME, AND ANTIBODIES THERETO
INVENTOR(S): Basch, Ross S., New York, NY, UNITED STATES
Zhang, Xin-Min, Bronx, NY, UNITED STATES
PATENT ASSIGNEE(S): New York University, New York, NY, UNITED STATES, 10012 (U.S. corporation)

NUMBER KIND DATE
---------- ------ --------
PATENT INFORMATION: US 2005119456 A1 20050602
US 6982317 B2 20060103
APPLICATION INFO.: US 2001-98770I A1 200III15 (9)

NUMBER DATE
---------- --------
PRIORITY INFORMATION: US 2000-248191P 200OIII5 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 2612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A gene in humans and mice, designated C21, encodes a family of proteins that play a role in transcriptional regulation. Two isoforms (.alpha. and .beta.) produced by alternative splicing has been identified in humans. A transgenic model was created that shows that over-expression of C21 in mouse hematopoietic cells alters myeloid development and suggests that members of this family are involved in regulating stem cell differentiation. Over-expressing C21 in 3T3 fibroblasts increases their resistance to apoptotic stimuli. The C21 protein forms a complex with a class of molecules that plays a critical role in transcription, the co-repressors of nuclear hormone receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2005:124996 USPATFULL <<LOGINID::20080228>>
TITLE: Methods of treating diseases and disorders by targeting multiple kinases
INVENTOR(S): Narla, Rama Krishna, San Diego, CA, UNITED STATES
Sakata, Steven, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005107386	A1	20050519
APPLICATION INFO.:	US 2004-994093	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-523859P	20031119 (60)
	US 2003-608929P	20031119 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the use of single agents, which are compounds that target two or more kinases simultaneously, thus substantially avoiding resistance to therapy. The invention provides methods for the use for, administration to, and treatment of individuals having a variety of diseases or conditions associated with the activity of two or more kinases, comprising administration of one or more single agents, either alone or in combination with other therapies for the same disease or condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2005:117698 USPATFULL <<LOGINID::20080228>>
TITLE: IL-18 binding proteins
INVENTOR(S): Ghayur, Tariq, Holliston, MA, UNITED STATES
Labkovsky, Boris, Marlborough, MA, UNITED STATES
Voss, Jeffrey W., Holden, MA, UNITED STATES
Green, Larry, San Francisco, CA, UNITED STATES
Babcook, John, Vancouver, CANADA
Jia, Xiao-chi, Los Angeles, CA, UNITED STATES
Wieler, James, Beverly, MA, UNITED STATES
Kang, Jaspal Singh, Surrey, CANADA
Hedberg, Brad, Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005100965	A1	20050512
APPLICATION INFO.:	US 2003-706689	A1	20031112 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Kenneth P. Zwicker, ESq., Abbott Bioresearch Center, Inc., 100 Research Drive, Worcester, MA, 01605-4314, US
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
LINE COUNT: 5993
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18

activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2005:38114 USPATFULL <<LOGINID::20080228>>
TITLE: Diamine derivatives of quinone and uses thereof
INVENTOR(S): Padia, Janak K., Germantown, MD, UNITED STATES
O'Brien, Sean, Gaithersburg, MD, UNITED STATES
Lu, Jiemin, Germantown, MD, UNITED STATES
Pikul, Stanislaw, Germantown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032794	A1	20050210
APPLICATION INFO.:	US 2004-758521	A1	20040115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492521P	20030805 (60)
	US 2003-523477P	20031119 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Alan J. Grant, Esq., c/o Carella, Byrne, Bain, Gilfillan,, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ, 07068
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 2539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Diamine derivatives of quinones, and related compounds, including salts thereof, that modulate the levels of gene expression in cellular systems, such as cancer cells, are disclosed, along with methods for preparing such compounds and derivatives, as well as pharmaceutical compositions containing these compounds and derivatives as active ingredients. Methods of using these as compounds and derivatives as therapeutic agents are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 24 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-444937 [45] WPIDS
DOC. NO. CPI: C2005-136216 [45]
TITLE: Use of pasireoxide in manufacturing a medicament for treating disorders of growth regulation, acromegaly, diabetes, obesity, Grave's disease, macular edema, cancer and sleep apnea in a selected patient population
DERWENT CLASS: B04; D16; P33
INVENTOR: SAULNIER M
PATENT ASSIGNEE: (NOVS-C) NOVARTIS AG; (NOVS-C) NOVARTIS PHARMA GMBH; (SAUL-I) SAULNIER M
COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2005053732	A1	20050616	(200545)*	EN	52	[0]
EP 1689429	A1	20060816	(200654)	EN		
MX 2006005952	A1	20060701	(200677)	ES		
AU 2004294269	A1	20050616	(200680)	EN		
BR 2004016925	A	20070116	(200708)	PT		
KR 2006118504	A	20061123	(200735)	KO		
CN 1905895	A	20070131	(200740)	ZH		
JP 2007518702	W	20070712	(200746)	JA	52	
IN 2006CN01842	P4	20070608	(200748)	EN		
US 20070275382	A1	20071129	(200780)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2005053732	A1	WO 2004-EP13350	20041124
AU 2004294269	A1	AU 2004-294269	20041124
BR 2004016925	A	BR 2004-16925	20041124
CN 1905895	A	CN 2004-80040917	20041124
EP 1689429	A1	EP 2004-798070	20041124
EP 1689429	A1	WO 2004-EP13350	20041124
MX 2006005952	A1	WO 2004-EP13350	20041124
BR 2004016925	A	WO 2004-EP13350	20041124
KR 2006118504	A	WO 2004-EP13350	20041124
JP 2007518702	W	WO 2004-EP13350	20041124
IN 2006CN01842	P4	WO 2004-EP13350	20041124
JP 2007518702	W	JP 2006-540373	20041124
KR 2006118504	A	KR 2006-710168	20060524
IN 2006CN01842	P4	IN 2006-CN1842	20060525
MX 2006005952	A1	MX 2006-5952	20060525
US 20070275382	A1 Provisional	US 2003-525079P	20031125
US 20070275382	A1	WO 2004-EP13350	20041124
US 20070275382	A1	US 2007-580778	20070323

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1689429	A1 Based on	WO 2005053732 A
MX 2006005952	A1 Based on	WO 2005053732 A
AU 2004294269	A1 Based on	WO 2005053732 A
BR 2004016925	A Based on	WO 2005053732 A
KR 2006118504	A Based on	WO 2005053732 A
JP 2007518702	W Based on	WO 2005053732 A

PRIORITY APPLN. INFO: US 2003-525079P 20031125
US 2007-580778 20070323

AN 2005-444937 [45] WPIDS

AB WO 2005053732 A1 UPAB: 20051222

NOVELTY - Use of pasireotide in the manufacture of a medicament for the treatment of disorders of growth regulation in a selected patient population, where the patient population is selected on the basis of the gene expression profile indicative of pasireotide efficacy by the patient to whom pasireotide is administered.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) treating a condition in a subject, where the condition is a condition for which somatostatin or a somatostatin analogue is indicated, comprising administering a compound to the subject, obtaining the gene expression profile of the subject, where the gene expression profile comprises the gene expression pattern of one or more genes, where the expression patterns of the one or more genes are a consequence of administration of the compound, and comparing the gene expression profile of the subject to whom the compound was administered to a biomarker gene expression profile indicative of efficacy of treatment by somatostatin or a somatostatin analogue, where a similarity in the gene expression profile of the subject to whom the compound was administered to the biomarker gene expression profile is indicative of efficacy of treatment with the compound;

(2) choosing a subject for inclusion in a clinical trial for determining the efficacy of a compound for a condition for which somatostatin or a somatostatin analogue is indicated, comprising administering the compound to the subject, obtaining the gene expression profile of the subject, where the gene expression profile comprises the gene expression pattern of one or more genes, where the expression patterns of the one or more genes are a consequence of administration of the compound, comparing the gene expression profile of the subject to whom the compound was administered to a biomarker gene expression profile indicative of efficacy of treatment by somatostatin or a somatostatin analogue, and including the subject in the clinical trial when the gene expression profile of the subject to whom the compound was administered is similar to the biomarker gene expression profile indicative of efficacy of treatment by somatostatin or a somatostatin analogue, or excluding the

subject from the clinical trial when the gene expression profile of the subject to whom the compound was administered is dissimilar to the biomarker gene expression profile indicative of efficacy of treatment by somatostatin or a somatostatin analogue;

(3) determining whether a compound has a therapeutic efficacy similar to that of somatostatin or a somatostatin analogue, comprising administering the compound to the subject, obtaining the gene expression profile of the subject, where the gene expression profile comprises the gene expression pattern of one or more genes, where the expression patterns of the one or more genes are a consequence of administration of the compound, comparing the gene expression profile of the subject to whom the compound was administered to a biomarker gene expression profile indicative of efficacy of treatment by somatostatin or a somatostatin analogue, and determining that the compound has a therapeutic efficacy similar to that of somatostatin or a somatostatin analogue when the gene expression profile of the subject to whom the compound was administered is similar to the biomarker gene expression profile of a subject to whom somatostatin or a somatostatin analogue is administered, or determining that the compound has a therapeutic efficacy different from that of somatostatin or a somatostatin analogue when the gene expression profile of the subject to whom the compound was administered is different from the biomarker gene expression profile of a subject to whom somatostatin or it somatostatin analogue is administered; and

(4) a kit for use in determining a treatment strategy for a condition, where the condition is a condition for which somatostatin or a somatostatin analogue is indicated, comprising a reagent for detecting a biomarker of efficacy of somatostatin or a somatostatin analogue treatment, a container for the reagent, and a written product on or in the container describing the use of the biomarker in determining a treatment strategy for the condition.

ACTIVITY - Cytostatic; Osteopathic; Anorectic; Antithyroid; Ophthalmological; Antidiabetic; CNS-Gen. No biological data given.

MECHANISM OF ACTION - IGF-Agonist-1; IGF-Agonist-2.

USE - The disorder of growth regulation treated is a tumor. The pasireotide is administered in a therapeutic or sub-therapeutic dose prior to determining the gene expression profile by the patient (all claimed). The compositions are also useful for treating acromegaly, diabetes, obesity, Grave's disease, macular edema, cancer and sleep apnea.

L7 ANSWER 22 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2004:50862 USPATFULL <<LOGINID::20080228>>
TITLE: Wound healing biomarkers
INVENTOR(S): Burslem, Martyn Frank, Sandwich, UNITED KINGDOM
Johnson, Claire Michelle, Sandwich, UNITED KINGDOM
Cooper, Lisa, London, UNITED KINGDOM
Martin, Paul, London, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038292	A1	20040226
APPLICATION INFO.:	US 2002-175184	A1	20020618 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-14869	20010618
	US 2001-305346P	20010713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 67123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides biomarkers such as genes and the corresponding mRNA transcripts or protein products that are identified as being involved in wound healing processes. Also provided are methods for identification of compounds useful for the treatment of wounds, wound healing disorders or inflammation and compounds identified by such

methods. Methods are provided for monitoring the progress of wound healing and for identification of individuals with wound healing disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:180721 USPATFULL <<LOGINID::20080228>>
TITLE: Agents implicated in endometriosis
INVENTOR(S): Pappa, Helen, Wokingham, UNITED KINGDOM
Lnenicek-Allen, Mirna, Wokingham, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003124551	A1	20030703
APPLICATION INFO.:	US 2002-139604	A1	20020503 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-GB4228, filed on 3 Nov 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-26081	19991103
	GB 1999-26074	19991103
	GB 1999-26079	19991103
	GB 1999-26076	19991103

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 3759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the discovery of genes and their products that are associated with the disease endometriosis. It has been discovered that cathepsin D, AEBP-1, stromelysin-3, cystatin B, protease inhibitor 1, sFRP4, gelsolin, IGFBP-3, dual specificity phosphatase 1, PAEP, immunoglobulin .lambda. chain, ferritin, complement component 3, pro-alpha-1 type III collagen, proline 4-hydroxylase, alpha-2 type I collagen, claudin-4, melanoma adhesion protein, procollagen C-endopeptidase enhancer, nascent-polypeptide-associated complex alpha polypeptide, elongation factor 1 alpha (EF-1.alpha.), vitamin D3 25 hydroxylase, CSRP-1, steroidogenic acute regulatory protein, apolipoprotein E, transcobalamin II, prosaposin, early growth response 1 (EGR1), ribosomal protein S6, adenosine deaminase RNA-specific protein, RAD21, guanine nucleotide binding protein beta polypeptide 2-like 1 (RACK1) and podocalyxin are all implicated in this disease. The discovery of these associations has clear implications for the diagnosis and treatment of endometriosis and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 24 WPIDS COPYRIGHT 2008 THE THOMSON CORP on STN
ACCESSION NUMBER: 2001-328804 [34] WPIDS
DOC. NO. CPI: C2001-100894 [34]
DOC. NO. NON-CPI: N2001-236604 [34]
TITLE: Screening for a gene or gene product associated with endometriosis, for diagnosing or treating endometriosis, comprises selecting a gene whose level of expression differs between healthy and diseased endometrium tissues
DERWENT CLASS: B04; D16; P14; S03
INVENTOR: LNENICEK M; LNENICEK M M T L; LNENICEK-ALLEN M; PAPPA H; PAPPA H M T L
PATENT ASSIGNEE: (LNEN-I) LNENICEK-ALLEN M; (METR-N) METRIS THERAPEUTICS LTD; (PAPP-I) PAPPA H
COUNTRY COUNT: 93

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2001032920	A2	20010510	(200134)*	EN	106	[7]
AU 2001011596	A	20010514	(200149)	EN		
EP 1238104	A2	20020911	(200267)	EN		
US 20030124551	A1	20030703	(200345)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION DATE
WO 2001032920	A2	WO 2000-GB4228 20001103
EP 1238104	A2	EP 2000-973040 20001103
EP 1238104	A2	WO 2000-GB4228 20001103
US 20030124551	A1 Cont of	WO 2000-GB4228 20001103
AU 2001011596	A	AU 2001-11596 20001103
US 20030124551	A1	US 2002-139604 20020503

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001011596	A Based on	WO 2001032920 A
EP 1238104	A2 Based on	WO 2001032920 A

PRIORITY APPLN. INFO: GB 1999-26074 19991103
GB 1999-26076 19991103
GB 1999-26079 19991103
GB 1999-26081 19991103

AN 2001-328804 [34] WPIDS

AB WO 2001032920 A2 UPAB: 20060117

NOVELTY - Screening (M1) for a gene or gene product associated with endometriosis comprises comparing the pattern of gene expression in a diseased endometrium tissue from a patient suffering from endometriosis to the pattern of gene expression in healthy endometrium tissue from the same patient, and selecting a gene whose level of expression differs between healthy and diseased tissues.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) detecting or diagnosing (M2) endometriosis disease in a patient comprising assessing the level of expression or biological activity of one or more genes or gene products identified by (M1), in a tissue from the patient and comparing the level of expression or biological activity to a control level of expression or biological activity, where the level of expression that is different to the control level is indicative of endometriosis;

(2) arrays comprising at least two:

(a) nucleic acid molecules, where each corresponds to the sequence of, is complementary to the sequence of, or hybridizes specifically to the gene implicated in endometriosis;

(b) different antibody species that are immunospecific with the gene product of the gene implicated in endometriosis; or

(c) polypeptide species, each comprising a gene product of the gene implicated in endometriosis, or its functional fragment or variant;

(3) monitoring (M3) the therapeutic effects of treatment of endometriosis disease in a patient comprising monitoring over a period the level of expression or the biological activity of the gene or gene product identified by (M1), in a tissue from the patient;

(4) treating endometriosis in a patient comprising:

(a) diagnosing the condition of the patient and correlating the result of the diagnosis with an appropriate treatment for the patient; or

(b) administering to the patient a compound that alters the expression or regulates the activity of the gene or gene product identified by the method;

(5) a gene or gene product identified by the method;

(6) identifying an agent that is effective in treating and/or diagnosing endometriosis comprising contacting the gene or gene product of (5), with one or more compounds suspected of possessing binding affinity for the gene or gene product, and selecting as the agent a compound that binds to the gene or gene product;

(7) kits useful for diagnosing endometriosis comprising:

(a) a first container with a nucleic acid probe that hybridizes under stringent conditions with the host nucleic acid that encodes the gene product, a second container with primers useful for amplifying the host nucleic acid, and instructions for using the probe and primers for facilitating the diagnosis of endometriosis; or

(b) one or more antibodies that bind to the gene product and a reagent useful for the detection of a binding reaction between the antibody and the gene product;

(8) a genetically-modified non-human animal that has been transformed to express higher, lower or absent levels of the gene or gene product of (5); and

(9) screening for an agent for treating endometriosis by contacting the genetically-modified non-human animal of (8) with a candidate agent and determining the effect of the agent on the endometriosis disease of the animal.

ACTIVITY - Gynecological;cytostatic. No biological data is given.

MECHANISM OF ACTION - Gene therapy; peptide therapy.

USE - The gene, gene product or their respective antagonist or agonist is useful as a pharmaceutical or in the manufacture of a medicament for diagnosing or treating endometriosis (claimed). The methods are useful for screening genes or gene products that are implicated in endometriosis. The methods are particularly useful in diagnosing endometriosis, as well as for screening for agents for treating endometriosis.

ADVANTAGE - Prior methods of diagnosing endometriosis are difficult and expensive, normally involving surgery. The present method allows the disease to be diagnosed and treated at early stage, is easier to perform and less expensive.

=> d his

L1 QUE (SKRP OR DUS19 OR CG7042 OR(DUAL (W) SPECIFICITY (W) PHOSPH

FILE 'MEDLINE, CAPLUS, SCISEARCH, USPATFULL, BIOSIS, TOXCENTER, EMBASE, ESBIOBASE, LIFESCI, BIOTECHNO, PASCAL, WPIDS' ENTERED AT 17:19:32 ON 28 FEB 2008

L2 4641 S L1
L3 12878385 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)
L4 1511 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)
L5 321 S (MODULATOR OR EFFECTOR OR INHIBITOR) (S) L4
L6 24 S (COMPOSITION OR KIT)(S) L5
L7 24 DUP REM L6 (0 DUPLICATES REMOVED)

=> log y